$AEMD News

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Stock Pulls Back: What's Going On?

Aethlon Medical Q1 2027 Earnings Call Transcript

Aethlon Medical Shares Surge Over 400% After Announcing North Immunology Merger

North Immunology joins biotech reverse merger boom with Aethlon deal

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

Aethlon Medical Pivots to Biotechnology with All-Stock Merger

Aethlon Medical To Merge With North Immunology; AEMD Holders To Retain ~4.75% Of Combined Company, With North Immunology Stockholders To Own ~95.25%; NewCo Expected To Have Pro Forma Equity Value Of ~$346.5M; Oversubscribed $180M Private Placement Expected To Fund NewCo Operations Into H2 2028

Aethlon Medical Has Received A Notice Of Allowance For A U.S. Patent Titled "DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF".

AEMD: Oncology Study Advances; Cost-Efficient Preclinical Activities Regarding Other Diseases Continue

Aethlon Medical, Inc. Q1 2027 Earnings Call Summary

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

Aethlon Medical, Inc. (AEMD) Q1 2027 Earnings Call Transcript

Aethlon Medical Q1 EPS $(4.02) Misses $(0.79) Estimate; Cash & Equivalents $4.9M

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

Patients In Aethlon Medical's Second Cohort Of Its Australian Oncology Feasibility Study Demonstrated Biological Changes

Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Aethlon Medical Prices $4M Follow-On Offering Of 5,633,009 Shares And Warrants At $0.7101 Per Unit

Aethlon Medical Files Prospectus For Offering Mixed Shelf